BHT

Quick links to important sections

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of BHT

What is BHT?

Butylated hydroxytoluene, commonly known as BHT, is a lipophilic (fat-soluble) organic compound that is chemically derived from phenol. It is primarily recognized for its antioxidant properties, which allow it to prevent or slow the oxidation of various materials.

Chemical Properties and Function

BHT works by acting as a synthetic analogue of Vitamin E. It functions as a free-radical scavenger, neutralizing highly reactive molecules that can cause oxidative stress and damage to cellular structures. Because it is fat-soluble, BHT is often found in products containing oils and fats, where it helps maintain stability and prevents rancidity.

Industrial and Commercial Uses

Due to its ability to preserve the integrity of chemical bonds, BHT is widely utilized across several industries:

  • Food Preservation: It is added to various food products, particularly fats, oils, and cereal-based items, to extend shelf life and maintain nutritional quality by preventing oxidative decay.
  • Cosmetics and Pharmaceuticals: BHT is frequently included in topical creams, lotions, and pharmaceutical formulations to stabilize active ingredients and prevent the breakdown of essential oils.
  • Industrial Applications: Beyond consumer goods, it is used in the manufacturing of rubber, plastics, and petroleum products to prevent the degradation of materials exposed to oxygen and high temperatures.

Research Context

In scientific literature, BHT has been studied for its interactions with lipid-coated viruses and its influence on cellular membrane stability. Researchers have investigated how its antioxidant mechanism might affect biological processes, particularly in the context of oxidative stress and longevity studies in various animal models.

What side effects are possible with BHT?

Possible Side Effects and Safety Information

The safety profile for BHT (Butylated Hydroxytoluene) is primarily derived from its use as an antioxidant and preservative, with regulatory status often linked to concentration limits in food and cosmetic products, rather than as an active pharmaceutical ingredient with established adverse event frequencies.

Adverse Reactions and Systemic Concerns

Official documents highlight potential safety concerns based on non-clinical data and human exposure studies:

  • Organ Toxicity: High oral doses in animal studies have been associated with toxic effects on the liver and kidneys. Animal models also suggest potential for toxic effects in lung tissue following dermal exposure.
  • Skin and Respiratory Effects: BHT has been designated as a human respiratory irritant by regulatory bodies. Predictive skin tests indicate it can be a mild irritant and moderate sensitizer, with case reports of positive reactions in individuals.
  • Endocrine Potential: Governmental safety assessments have noted concerns regarding BHT's potential to possess endocrine disrupting properties.
  • Carcinogenesis: Some animal feeding studies have shown a potential link to tumor promotion (e.g., in the liver and lungs) at certain high doses, although other studies indicate no effect or even an anticarcinogenic effect depending on the context of exposure.

Regulatory Status and Limitations

  • Safety Classification: The U.S. Food and Drug Administration (FDA) generally classifies BHT as "Generally Recognized as Safe (GRAS)" when used within specified limits as a food additive.
  • Exposure Limitations: Due to safety considerations, regulatory authorities, such as the European Commission, have established maximum concentration limits for BHT's use in cosmetic formulations (e.g., up to 0.8% in certain products).

Risk management for BHT is focused on controlling the level of exposure to mitigate potential systemic and local risks documented in the regulatory literature.

Overdose and Emergency Response

Overdose and When to Seek Help

Information regarding Betahistine (BHT) overdose is based strictly on documentation from government regulatory authorities and prescribing information. Symptoms in documented overdoses of up to 640 mg are generally described as mild to moderate.


Documented Overdose Manifestations

Overdose presentations typically affect the gastrointestinal and central nervous systems. Officially documented symptoms include:

  • Mild Symptoms: Nausea, vomiting, abdominal pain, dyspepsia, dry mouth, and somnolence (drowsiness).
  • Severe Outcomes: Convulsion (seizures), pulmonary complications, and cardiac complications have been reported, particularly in cases of intentional high-dose or polydrug overdose.

Required Emergency Actions

In the event of a suspected overdose, it is essential to follow regulatory guidance for emergency response. No specific antidote for Betahistine is available; management focuses on supportive care.

Situation Action Required (As Labeled)
Serious Symptoms Seek immediate medical attention (e.g., passing out, trouble breathing, or convulsion).
General Overdose Contact a doctor, go to the nearest Emergency Department, or call the regional Poison Control Centre.

Standard supportive measures should be followed. Recommended procedural steps may include gastric lavage and the administration of activated charcoal within one hour after ingestion.

Therapeutic Uses of BHT

Betahistine (BHT) is generally applied across therapeutic domains where additional symptomatic support is needed for chronic inner ear conditions. It is commonly used to help with symptoms associated with Ménière's disease and other vestibular disorders, and may contribute to easing the overall symptom load linked to inner ear imbalance.

This medication may be part of symptomatic management for symptoms related to systemic imbalance, recurrent, episodic manifestations of vertigo, and secondary issues like tinnitus (ringing in the ears) and ear fullness. It is relevant when supportive symptom management is appropriate, particularly in conditions characterized by periods of heightened symptoms.

Quick Fact: Support for Symptoms of Recurrent Dizziness

The medication may assist with easing symptoms associated with acute or episodic changes, such as spinning sensations, and is relevant when supportive symptom management is appropriate.


Management of Symptoms and Functional Improvement

This treatment is generally applied across conditions characterized by recurrent or episodic manifestations. It supports the patient during difficult episodes by easing distress and is commonly used to help with symptoms that interfere with daily functioning. This ongoing support may assist with maintaining a sense of stability when symptoms are more noticeable, and may assist with maintaining functional stability.

Eligibility and Restrictions for Use

Who Can and Cannot Use Betahistine (BHT)

Official regulatory information strictly defines the populations eligible for Betahistine use.

Eligibility Scope

The medicine is officially approved for use in adults (18 years and over). The drug is not recommended for children and adolescents under 18 years of age because sufficient regulatory data on safety and efficacy in this pediatric group is currently unavailable.

Absolute Contraindications

Betahistine must not be used by patients with a history of phaeochromocytoma (an adrenal gland tumor), as its use is formally prohibited due to the theoretical risk of inducing a hypertensive crisis. It is also contraindicated in individuals with known hypersensitivity to the active substance or any excipients.

Conditions Requiring Caution and Restrictions

Official labeling requires caution and careful monitoring for patients with certain pre-existing conditions, including bronchial asthma and severe hypotension (very low blood pressure). Specific caution is also advised for patients with a history of allergic conditions like urticaria or allergic rhinitis. While specific clinical trials are lacking, post-marketing experience suggests that no dose adjustment is necessary for patients with renal or hepatic impairment.

Pregnancy and Lactation

Use during pregnancy should be avoided as a precautionary measure due to insufficient human safety data. For breastfeeding women, use is generally not recommended because it is unknown if Betahistine is excreted into human milk.

What should I know about interactions with other medicines?

Interactions with other medicines and products

BHT (Butylated Hydroxytoluene) is primarily documented in global regulatory sources as a chemical substance and antioxidant approved for use in food, cosmetic products, and some non-prescription preparations, rather than as an active pharmaceutical ingredient in prescription drug labeling. Consequently, official government documents do not specify a list of contra-indicated or significantly interacting therapeutic medicines for BHT as a drug.

Official Regulatory Constraints

The documented interaction constraints for BHT are tied to its use as an additive, focusing on combination restrictions and maximum concentration limits when mixed with similar chemical substances in consumer products. The official regulatory profile is structured around compliance with food and cosmetic safety standards, not drug-drug interactions.

Interaction Context Regulatory Constraint
Combination with BHA (Butylated Hydroxyanisole) Total concentration of BHA and BHT must not exceed specified parts per million (ppm) limitations in regulated food categories (e.g., dry breakfast cereals).
Cosmetic Products Use is restricted, with varying maximum concentration limits (e.g., 0.8% in general rinse-off/leave-on products; 0.1% in toothpaste) depending on the product type.

These constraints define the maximum allowable combined levels in finished products as mandated by agencies like the FDA and European Commission. There are no specific timing-based rules or required procedural restrictions for co-administration with other medicines noted in authoritative interaction sections.

Mechanism of Action

How BHT Works

BHT (Butylated hydroxytoluene) is a lipophilic phenolic compound whose primary mechanism of action involves functioning as a free radical scavenger within cellular environments. Its lipophilicity allows it to integrate readily into phospholipid bilayers of cell membranes, including mitochondrial and nuclear membranes.

BHT interacts directly with highly reactive free radicals, particularly peroxy radicals ( RO2cdot), by donating a hydrogen atom to quench their reactivity. This chemical action interrupts the autocatalytic chain reaction of lipid peroxidation, a key pathway in oxidative stress. The resulting biochemical consequence is the stabilization of unsaturated lipids and the interruption of further oxidative damage, thereby maintaining a reduced state within the targeted cellular compartment.

Furthermore, BHT influences intracellular signaling cascades. Evidence indicates modulation of early molecular steps related to pathways such as PI3K/AKT and MAPK. By modulating these cascades, the compound affects downstream signaling activity that determines the progression of intrinsic and extrinsic cell death pathways. Its integration into membranes also alters the biophysical properties of the bilayer, which modifies barrier integrity and transmembrane protein function.

Dosage and Administration Information

How Betahistine (BHT) is Used: Administration Overview

Betahistine is administered via the oral route, typically as tablets. Its application involves specific parameters regarding dosing, frequency, and administration conditions.


Dosing and Administration

Instruction Domain General Administration Parameters
Approved Administration Route Oral (by mouth) via tablets or, where available, oral solution.
Tablet Strengths Commonly available strengths are 8 mg, 16 mg, and 24 mg (as dihydrochloride).
Adult Dosing Range The total daily dose is typically 24 mg to 48 mg, adjusted to individual response.
Maximum Daily Dose The maximum recommended daily intake is 48 mg.

Schedule, Frequency, and Duration

To maintain consistent concentrations, the total daily dose is taken in divided doses, generally administered two to three times per day. Tablets are taken preferably with meals or after food. This administration approach is used to minimize potential mild gastrointestinal discomfort.

Treatment with Betahistine is often considered long-term. While some response may be observed after a couple of weeks, significant results are frequently observed after several months of continuous administration.


Use in Specific Populations

Standard parameters provide information for specific groups:

  • Pediatric Population (Under 18): Use is not recommended due to a lack of sufficient data on efficacy and safety in this age group.
  • Older Adults and Impaired Function: No specific dose adjustments are typically deemed necessary for older adults or for patients with renal or hepatic impairment, based on post-marketing experience.

Recent Clinical Evidence

BHT: Recent Clinical Evidence


Evidence for Use in Ménière's Disease and Recurrent Vertigo

Research exploring Betahistine's use in conditions characterized by fluctuating or episodic manifestations, such as Ménière's disease and related conditions characterized by recurrent episodes of spinning sensations, primarily relies on Randomized Controlled Trials (RCTs). These trials assign patient groups by chance to receive either the medicine or a comparison treatment, such as a placebo. The findings from these trials are synthesized in Systematic Reviews and Meta-analyses to contribute to the broader evidence landscape.

The studies monitored were conducted during periods of increased symptom activity and research examined how adult patients experiencing fluctuating symptoms reported their experience. The main outcomes monitored were the frequency and perceived severity of vertigo episodes, and outcomes reflecting daily functioning or activity level. Studies report how symptoms evolved, with some trials describing patterns related to outcomes describing episodic or acute changes. However, evidence quality varies across studies, and the findings have been mixed across systematic literature reviews.


Evidence for Related Inner Ear Symptoms: Tinnitus and Ear Fullness

In addition to vertigo, Betahistine was evaluated in research for its relevance in managing associated symptoms like tinnitus (ringing in the ears) and the sensation of ear fullness. Research exploring these aspects typically studies monitored data collected as secondary outcomes within the main RCTs. Reports from the trials described some patterns related to these symptoms; however, the data derived from these secondary outcomes are less consistent. Because these symptoms are typically assessed as secondary goals of the research, data for certain groups remain insufficient.


Long-Term Studies and Follow-Up Duration

The core research explored Betahistine in studies conducted over short- to intermediate-term follow-up durations. While the evidence provides insight into short-term changes, there is limited information for long-term outcomes regarding the sustained measurements of the medicine on the overall condition or the durability of functional stability. Therefore, the long-term effects are not fully established, and continued research is ongoing to provide a clearer context.

Frequently Asked Questions (FAQ)

Common questions about BHT (FAQ)


Q: How long does the effect of a BHT dose typically last?

Official prescribing information indicates that Betahistine is typically taken in divided doses, usually two or three times each day. This is done to maintain a consistent amount of the medication in the body.


Q: What happens if I miss a scheduled dose of BHT?

If a dose is missed, regulatory patient leaflets advise skipping the forgotten dose entirely. The recommended action is to resume the schedule by taking the next dose at its usual time and not taking two doses together to compensate.


Q: Is it normal to feel tired when first starting BHT?

According to official product information, feelings of tiredness (fatigue) are listed as a rare side effect of Betahistine. Drowsiness has also been reported, though it is considered very rare.


Q: Can BHT cause problems with sleeping?

Difficulty sleeping, also known as insomnia, is a side effect that has been reported in post-marketing surveillance. Regulatory documents classify this as a less serious or rare occurrence.


Q: Are there any common supplements that should be avoided while taking BHT?

Official regulatory warnings indicate that patients should disclose all medicines they are taking, including any natural or herbal remedies. This is because the safety and effects of combining Betahistine with many supplements have not been sufficiently studied or tested in official trials.


Q: What are the most commonly reported mild side effects of BHT?

The most commonly reported side effects, which may affect up to 1 in 10 people, include headache and minor stomach issues. These stomach issues are typically described as nausea or indigestion.


Q: What is the difference between BHT and the drug XYZ that treats the same condition?

Regulatory and governmental drug documents do not typically provide comparative information between Betahistine and other medicines used for similar conditions. Official sources focus on the safety and efficacy of the drug itself, not on comparative claims.


Q: Are there any long-term health risks associated with taking BHT for many years?

Long-term use of Betahistine has been monitored through post-marketing surveillance for many years. This data suggests a generally satisfactory safety profile, with official sources indicating no major concerns regarding chronic toxicity or potential for causing tumors.


Q: Does BHT interact with common pain relievers like ibuprofen or acetaminophen?

Official interaction sections do not list specific drug-drug interactions between Betahistine and common pain relievers like ibuprofen or acetaminophen. However, official labeling does note potential interactions with other classes of medicines, such as MAO inhibitors and certain antihistamines.


Q: How does BHT affect driving or operating machinery?

According to official product documents, the medication itself is not expected to impair the ability to drive or operate machinery. However, because the underlying condition Betahistine is used for can cause dizziness and imbalance, patients are advised to observe how their symptoms may affect their safety.


Q: What should I do if a side effect of BHT seems to get worse?

Official patient leaflets recommend that if a side effect becomes severe, or if the provided advice on coping with mild side effects is insufficient, consultation is warranted. Official information indicates that consultation with a qualified healthcare professional, such as a doctor or pharmacist, is warranted for individual guidance.


Q: Can I drink alcohol moderately while I am on BHT treatment?

Official patient information sources often advise to limit or avoid the consumption of alcohol while undergoing treatment with Betahistine. This general advice is provided as a precaution.


Q: Are headaches a frequent side effect reported with BHT?

Yes, official documents list headache as one of the common side effects of Betahistine. It is one of the most frequently reported mild effects in clinical trials and post-marketing data.


Q: Does BHT cause any changes in mood or anxiety levels?

Specific changes to common mood or anxiety levels are generally not listed in regulatory sections on side effects. However, official information does note that very rare undesirable effects, such as confusional states or hallucinations, have been reported.


Q: Can BHT be taken alongside common heartburn or antacid medications?

There is no specific official interaction listed that prohibits taking Betahistine alongside common heartburn or antacid medications. Patient advice often suggests using an antacid to help ease mild indigestion, indicating co-administration is generally considered acceptable.


Q: What are the rare but serious side effects associated with BHT?

Rare but serious events are described in the regulatory safety profile of Betahistine, including severe allergic reactions such as angioedema (swelling beneath the skin) and anaphylaxis. Additionally, very rare neurological events, like convulsions, have been noted.


Q: Does BHT have any common interactions with herbal remedies?

Official regulatory labels indicate that consultation with a healthcare provider is noted regarding the co-administration of Betahistine and any herbal remedies or supplements. This recommendation is due to the lack of sufficient safety data regarding these combinations.


Q: Can I split or crush BHT tablets if I have trouble swallowing them?

Official product information states that the score line found on certain tablets is intended to facilitate breaking the tablet for easier swallowing, if necessary. The document states that this action is not meant for dividing the tablet into exact half-doses.


Q: Is the effectiveness of BHT affected by a person's diet?

Official data on the medicine’s absorption indicates that taking Betahistine with food slows down the rate at which the body absorbs it. However, the total amount of medicine absorbed remains similar, meaning diet is not documented to affect its overall effectiveness.


Q: What does 'contraindicated' mean in the context of BHT use?

When a medicine is described as "contraindicated," it means there are specific diseases or conditions for which it must not be used. For Betahistine, these conditions include phaeochromocytoma and known hypersensitivity, because using the drug in these situations could lead to risks that outweigh any potential benefit.


Q: What are the main findings from the most recent large-scale research on BHT?

Regulatory summaries indicate that the quality of research evidence for Betahistine is mixed across systematic reviews. While studies have been conducted, official reviews often state there is insufficient evidence from high-quality trials to definitively conclude that the drug prevents vertigo attacks when compared directly against a placebo.


Q: What precautions are listed for patients with heart problems who take BHT?

Official labeling includes precautions for patients with specific cardiovascular concerns, such as severe hypotension (very low blood pressure). This is listed as a condition requiring caution and monitoring.


Q: Is the side effect profile of BHT different for men and women?

Official regulatory documents and post-marketing surveillance reports do not indicate a sex-specific difference in the side effect profile of Betahistine. The safety profile is generally reported the same for both men and women.


Q: How quickly does BHT start to work after taking it?

Official sources state that while some individuals may observe improvement after a couple of weeks of treatment, the most optimal results are frequently noted after continuous administration over several months. This is why the treatment is often considered a long-term therapy.


Q: Do studies exist that compare BHT use over six months versus one year?

Treatment with Betahistine may last up to a year or longer, but official regulatory sources do not cite dedicated, high-quality clinical trials designed specifically to compare the drug's effectiveness between a six-month duration and a one-year duration. Evidence focuses on short- and intermediate-term use.


Q: Is it safe to take BHT with high blood pressure medication?

While there are no specific drug-drug contraindications listed for high blood pressure medication, official labeling advises caution for patients who have severe hypotension (very low blood pressure). This general caution is noted because Betahistine has mild blood pressure effects.

How should BHT be stored and disposed of?

How to Store and Dispose of Betahistine (BHT)

Storage and disposal must strictly adhere to the official requirements set out in government regulatory documentation.

Storage Requirements

Betahistine tablets are generally required to be stored at a temperature below 25°C or 30°C, depending on the specific regional product labeling. The medicine must be kept in its original package and blister carton to ensure protection from light and moisture, and to maintain its stability until the expiry date. Consistent with all medication safety rules, the product must be kept out of the sight and reach of children.

Disposal Instructions

Unused or expired Betahistine must be handled as pharmaceutical waste. Official instructions state that the medicine must not be discarded via household waste or flushed down the toilet. The regulatory procedure requires patients to return unused medicine to a pharmacy or designated collection point for safe and environmentally compliant disposal.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of BHT found in:

A-Z Index: